Adaptive Biotechnologies Corporation (ADPT)

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a...

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial...

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial...

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a...

Form 4 - Statement of changes in beneficial ownership of securities